Researchers described a new panel of human monoclonal antibodies that potently neutralize clade 2.3.4.4b H5N1 hemagglutinin in vitro and mapped their binding sites at molecular resolution. Led by Alzua, León and Yellin and published in Nature Communications, the work details antibody sequences, epitope specificity and neutralization breadth across recent H5N1 isolates. The findings provide candidate lead molecules for therapeutic development and tools to inform vaccine antigen selection against emergent avian influenza clades.